[go: up one dir, main page]

WO2024215709A3 - Decoy icam-1 receptor proteins and treatment methods - Google Patents

Decoy icam-1 receptor proteins and treatment methods Download PDF

Info

Publication number
WO2024215709A3
WO2024215709A3 PCT/US2024/023798 US2024023798W WO2024215709A3 WO 2024215709 A3 WO2024215709 A3 WO 2024215709A3 US 2024023798 W US2024023798 W US 2024023798W WO 2024215709 A3 WO2024215709 A3 WO 2024215709A3
Authority
WO
WIPO (PCT)
Prior art keywords
icam
receptor proteins
treatment methods
expression vectors
decoy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/023798
Other languages
French (fr)
Other versions
WO2024215709A2 (en
Inventor
Todd Christopher BRADLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Mercy Hospital
Original Assignee
Childrens Mercy Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Mercy Hospital filed Critical Childrens Mercy Hospital
Publication of WO2024215709A2 publication Critical patent/WO2024215709A2/en
Publication of WO2024215709A3 publication Critical patent/WO2024215709A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Expression vectors, preferably mRNA expression vectors, encoding for soluble ICAM-1 for increasing ICAM-1 levels in a subject in need thereof, as decoy receptor proteins for endogenous transmembrane ICAM-1. Therapeutic or prophylactic formulations of the same. Therapeutic or prophylactic treatment methods using the same, such that the administration of the composition results in expression, translation, and/or activity of the protein encoded by the expression vector in the subject, wherein the protein is soluble ICAM-1. Uses of mRNA expression vectors to deliver soluble ICAM-1 for both the prevention and treatment of RSV to reduce RSV disease severity and prevent death from viral infection.
PCT/US2024/023798 2023-04-10 2024-04-10 Decoy icam-1 receptor proteins and treatment methods Pending WO2024215709A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363495145P 2023-04-10 2023-04-10
US63/495,145 2023-04-10

Publications (2)

Publication Number Publication Date
WO2024215709A2 WO2024215709A2 (en) 2024-10-17
WO2024215709A3 true WO2024215709A3 (en) 2024-12-26

Family

ID=93060056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/023798 Pending WO2024215709A2 (en) 2023-04-10 2024-04-10 Decoy icam-1 receptor proteins and treatment methods

Country Status (1)

Country Link
WO (1) WO2024215709A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
US20030143236A1 (en) * 1990-07-20 2003-07-31 Jeffrey M. Greve Multimeric forms of human rhinovirus receptor protein
US20110052601A1 (en) * 1999-03-11 2011-03-03 University Of South Florida Compositions comprising anti-icam-1 antibodies
US20220002695A1 (en) * 2019-03-22 2022-01-06 Spotlight Therapeutics Targeted active gene editing agent and methods of use
WO2022241480A1 (en) * 2021-05-13 2022-11-17 Technion Research & Development Foundation Limited Methods and compositions for treatment of viral infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
US20030143236A1 (en) * 1990-07-20 2003-07-31 Jeffrey M. Greve Multimeric forms of human rhinovirus receptor protein
US20110052601A1 (en) * 1999-03-11 2011-03-03 University Of South Florida Compositions comprising anti-icam-1 antibodies
US20220002695A1 (en) * 2019-03-22 2022-01-06 Spotlight Therapeutics Targeted active gene editing agent and methods of use
WO2022241480A1 (en) * 2021-05-13 2022-11-17 Technion Research & Development Foundation Limited Methods and compositions for treatment of viral infection

Also Published As

Publication number Publication date
WO2024215709A2 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US9561263B2 (en) Treatment of inflammatory illnesses with ACE2
CN102470163B (en) skin external preparation composition
US10077293B2 (en) Antimicrobial peptide analogues derived from abalone (Haliotis discus) and antimicrobial pharmaceutical composition containing the same
US10471142B2 (en) Combination therapy using immunoglobulin and C1-Inhibitor
US20110053835A1 (en) Antimicrobial peptides derived from cap18
MX2008009208A (en) Treatment of ischemic disease using thrombopoietin.
KR20140018577A (en) Compositions for preventing or treating of eye diseases
AU2004207118B2 (en) Peptide inhibitors of toxins derived from LL-37
AU2017252344B2 (en) Diagnosis of immune_activation using CLEVER-1, TNF-alpha and HLA-DR binding agents
US12006343B2 (en) C4BP-based compounds for treating immunological diseases
WO2024215709A3 (en) Decoy icam-1 receptor proteins and treatment methods
US20180117126A1 (en) Treatment of inflammatory illnesses with ace2
JP7440126B2 (en) Peptide-containing composition for treating neoplastic lesions
JP2015131796A (en) Short activating peptide used for angiotensin i-converting enzyme inhibition and blood pressure reduction
KR102176810B1 (en) Composition for promoting hair growth
Tablets INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES
KR102176811B1 (en) Composition for promoting hair growth
US20230293459A1 (en) Oleylcysteineamide or derivatives thereof and their use in therapy
WO2024211244A3 (en) Novel compounds and uses thereof
JP7134461B2 (en) Malaria therapeutic agent, malaria preventive agent and antimalarial natural immunostimulant
WO2024014959A3 (en) Micelle-generating formulations with improved hydrophobicity
JP2002199849A5 (en)
Miyakoshi et al. Mitogenic substances in staphage lysate (SPL)
HK1200334B (en) Combination therapy using immunoglobulin and c1-inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24789336

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE